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Objective:We sought to promote myocardial repair using urinary bladder matrix incorporated with a fusion pro-
tein that combined hepatocyte growth factor and fibronectin collagen-binding domain in a porcine model. Col-
lagen-binding domain acted as an intermediary to promote hepatocyte growth factor binding and enhance
hepatocyte growth factor stability within urinary bladder matrix.
Methods: Urinary bladder matrix incorporated with collagen-binding domain and hepatocyte growth factor was
implanted into the porcine right ventricular wall (F group) to repair a surgically created defect. Untreated urinary
bladder matrix patches (U group) and Dacron patches (D group) served as controls (N ¼ 5/group). Electrome-
chanical mapping was performed 60 days after surgery. Linear local shortening was used to assess regional con-
tractility, and electrical activity was recorded.
Results: Linear local shortening was significantly improved in the F group compared with controls (F: 0.51%
1.57% [P<.05], U:1.06% 1.84%, D:2.72% 2.59%), whereas it was inferior to the normal myocardium
(13.7%  4.3%; P< .05). Mean electrical activity was 1.49  0.82 mV in the F group, which was statistically
greater than in the control groups (U: 0.93  0.71 mV; D: 0.30  0.22 mV; P< .05) and less than the normal
myocardium (8.24  2.49 mV; P< .05). Histologic examination showed predominant a-smooth muscle actin
positive cells with the F group showing the thickest layer and the D group showing the thinnest layer, with an
endocardial endothelial monolayer. Scattered isolated islands of a-actinin positive cells were observed only in
the F group, but not in the controls, suggesting the presence of cardiomyocytes.
Conclusion: The collagen-binding domain/hepatocyte growth factor/urinary bladder matrix patch demonstrated
increased contractility and electrical activity compared with urinary bladder matrix alone or Dacron and facilitated
a homogeneous repopulation of host cells. Urinary bladder matrix incorporated with collagen-binding domain
and hepatocyte growth factor may contribute to constructive myocardial remodeling.E
TBiologic scaffold materials derived from naturally occurring
extracellular matrix (ECM) have shown the ability to pro-
mote site-specific, constructive remodeling in a variety of
body systems in both preclinical studies and clinical prac-
tice.1,2 Recently, an ECM scaffold derived from the base-
ment membrane and lamina propria layers of the porcine
urinary bladder, referred to as urinary bladder matrix
(UBM), was evaluated for repair of myocardial tissue.
UBM showed some promise for myocardial repair, with
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trical activity and mechanical function, but was inferior to
normal myocardial tissue 60 days after repair.3-5 The pur-
pose of the present study was to determine whether the addi-
tion of a biologically active factor, specifically, hepatocyte
growth factor (HGF), may accelerate the remodeling re-
sponse of injured myocardial tissue.
HGF was chosen for investigation in this model because it
possesses a potent mitogenic effect on endothelial cells and
stimulates angiogenesis.6,7 Urbanek and colleagues8 re-
ported that the intramyocardial injection of HGF facilitated
the migration and proliferation of c-kit positive cells, which
differentiate into small, functional myocytes. HGF also en-
hances ‘‘cell-to-cell’’ and ‘‘cell-to-ECM’’ adhesion through
activation of a matrix degradation pathway, which facilitates
repopulation of tissues with cells.9 In addition, HGF has
been shown to suppress fibrosis that is characteristic of mal-
adaptive remodeling of infarcted hearts.10,11
The direct addition of HGF to UBMwould be expected to
yield only transient effects because HGF would likely rap-
idly elute from the UBM surface. To prolong the presence
of HGF in the UBM, a fusion protein combining fibronectinrdiovascular Surgery c Volume 136, Number 5 1309
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TAbbreviations and Acronyms
a-SMA ¼ a-smooth muscle actin
CBD ¼ collagen-binding domain
ECM ¼ extracellular matrix
HGF ¼ hepatocyte growth factor
LLS ¼ linear local shortening
MHC ¼ beta-myosin heavy chain
RV ¼ right ventricular
UBM ¼ urinary bladder matrix
VEGF ¼ vascular endothelial growth factor
collagen-binding domain (CBD) and HGF was used in this
study.12 CBD has a high affinity exclusively for collagen
and gelatin. In a previous study using CBD-HGF, enhanced
early endothelialization and site-specific remodeling were
observed in a decellularized porcine aortic valve.13 We hy-
pothesize that CBD-HGF will alter the phenotypic profile
of cells that populate the remodeled UBM cardiac patch
and enhance cardiac function.
MATERIALS AND METHODS
Urinary Bladder Matrix Scaffold Preparation
UBM scaffolds were prepared as described previously.3 Briefly, the
basement membrane of the tunica epithelialis mucosa and the subjacent tu-
nica propria of the porcine urinary bladder, collectively termed ‘‘UBM,’’
was mechanically isolated and then decellularized and disinfected by im-
mersion in 0.1% (v/v) peracetic acid, 4% (v/v) ethanol, and 96% (v/v) de-
ionized water for 2 hours. The UBMmaterial was then washed twice for 15
minutes with phosphate-buffered saline (pH¼ 7.4) and twice for 15 minutes
with deionized water.
Four hydrated sheets of UBM were stacked in such a manner that the
basement membrane surface was the outermost surface on the top and bot-
tom of the stack. This orientation of sheets was chosen to promote endothe-
lial cell growth on the luminal aspect of the scaffold regardless of the
orientation of the scaffold.14 The 4-layer construct was laminated by a vac-
uum-pressing technique. The construct was placed between 2 perforated
stainless steel sheets, and the stainless steel plates were placed between
sheets of sterile gauze. The entire construct was then sealed in vacuum bag-
ging and subjected to a vacuum of 710 to 730 mm Hg for approximately 8
hours. It was finally sterilized by exposure to ethylene oxide. The thickness
of each UBM scaffold was approximately 1 mm in the dry form and 1.5 mm
in the rehydrated form.
Preparation of Collagen-Binding Domain/
Hepatocyte Growth Factor
CBD was fused to the amino terminus of mature HGF with an inserted
amino acid sequence using the baculovirus technique, and CBD-HGF
was purified as previously described.12 The amount of CBD-HGF present
was measured by enzyme-linked immunosorbent assay and expressed as
the amount of recombinant HGF (PeproTech, Rocky Hill, NJ).
Incorporation of Collagen-Binding Domain/
Hepatocyte Growth Factor and Urinary Bladder
Matrix
The incorporation of CBD-HGF to UBM was performed under sterile
conditions. CBD-HGF (50 mg) was incubated at 37C for 15 minutes after1310 The Journal of Thoracic and Cardiovascular Suadding fetal bovine serum (20 mL), which transformed single chains of the
CBD-HGF into heterodimers (active form). The UBM scaffolds (25 3 25
mm) were rehydrated with saline and then soaked in an activated CBD-
HGF solution (1 mg/mL; 25 mL/patch) for 24 hours at 4C. Finally, the
CBD-HGF solution was decanted, and the patches were rinsed with phos-
phate-buffered saline (50 mL/patch) before surgery.
Quantitative Determination of Hepatocyte Growth
Factor
The amount of HGF in preimplant CBD-HGF-UBM patches (N ¼ 5)
wasmeasured by enzyme-linked immunosorbent assay (HGF Immunoassay
Kit, Biosource, Camarillo, Calif) after protein extraction of homogenized
patches using a lysis buffer (Tissue Extraction Reagent I, Biosource). Re-
combinant (r)HGF-UBM patches (N ¼ 5), which were subjected to the
same incorporation process except for the use of rHGF (PeproTech) in place
of CBD-HGF, and untreated UBM patches (N ¼ 5) served as controls.
Cell Proliferation Assay
UBM discs (5 mm in diameter, thickness of 0.3 mm) were washed with
phosphate-buffered saline and then placed in wells of 96-well plates (Nun-
clon, Nalge Nunc International, Roskilde, Denmark). The discs were incu-
bated for 2 hours at 37C in solutions of CBD-HGF or rHGF (0, 80, or 400
ng/disc in phosphate-buffered saline). Each scaffold was washed several
times. Human umbilical vein endothelial cells (Lonza, Walkersville, Md)
were seeded (5000 cells/well) and cultured for 7 days in EBM2 medium
(Lonza) supplemented with 0.5% serum and insulin-like growth factor
but without other angiogenic factors (endothelial growth factor, fibroblast
growth factor-2, and vascular endothelial growth factor [VEGF]). The cell
number was measured using WST-1 reagent (Dojindo, Kumamoto, Japan)
as previously described.12
Myocardial Repair in a Porcine Model
Yorkshire swine (40–50 kg) were anesthetized and placed in a left re-
cumbent position. The pericardiotomy was performed, and accordingly
the heart was exposed via a right anterolateral thoracotomy in the fourth in-
tercostal space. After the positioning of a tangential clamp on the right ven-
tricle, a small portion in full thickness of the right ventricular (RV) free wall
was substituted with a CBD-HGF-UBM patch (25 mm in diameter) with
a 5-0 continuous polypropylene suture (F group, N¼ 5) (Figure 1, A). Rou-
tine chest closure was performed. At 60 days after implantation, the animals
were subjected to electromechanical mapping and euthanized for further ex-
amination. Swine similarly receiving untreated UBM (U group, N ¼ 5) or
Dacron (thickness of 0.76 mm) (D group, N¼ 5) were used as controls (Fig-
ure 1, B). The 60-day time point was chosen because naturally occurring
ECM was typically degraded by this time.15,16
The study protocol was approved by the Institutional Animal Care and
Use Committee of the University of Pittsburgh. All animals received hu-
mane care in compliance with theGuide for the Care and Use of Laboratory
Animals, published by the National Institutes of Health (1996).
Electromechanical Mapping
Electromechanical mapping was performed with the NOGA mapping
system (Biosense Webster Inc, Diamond Bar, Calif). The system uses syn-
chronous extracorporeal magnetic fields projected into the thoracic space to
determine the location and orientation of a sensormounted near the distal elec-
trode of a deflectable bipolar mapping catheter (NOGA-Star, Biosense Web-
ster Inc, Diamond Bar, Calif), which can be used to access the endocardial
surface.17 An intracardiac echocardiography system (AcuNAV; Acuson Sie-
mens, Mountain View, Calif) was use together with NOGA to ensure proper
placement of theNOGA-Star catheter. TheAcuNAVsystem consists of a 10F
deflectable catheter incorporating a phased-array transducer with programma-
ble operating frequency.18,19 Endocardial mapping of the entire endocardialrgery c November 2008
Ota et al Evolving TechnologyFIGURE 1. Intraoperative view after implantation. A, CBD-HGF-UBM patch. B, Dacron patch. C, CBD-HGF-UBM patch 60 days after implantation. The
patch is covered with a thin connective tissue with little adhesion. No aneurysm is seen (arrow). D, Dacron patch 60 days after implantation (excised heart).
Severe adhesion (already removed) and deformity of the patch are shown (arrow). E, Cross-section of CBD-HGF-UBM patch. The thickness of the patch area
approaches that of the normal myocardium. CBD-HGF-UBM, Collagen-binding domain/hepatocyte growth factor/urinary bladder matrix.E
Tsurface was performed during sinus rhythm. The acquired point density for
non-free RV walls was 5/cm2; the density for the RV free wall was 10/cm2.
Regional contractility was evaluated by calculating the linear local short-
ening (LLS) (LLS>9%; normal contractility, 9%>LLS>0%; hypoki-
netic, 0% > LLS; dyskinetic). The algorithm calculated the fractional
shortening of regional endocardial surface at end-systolic phase as previ-
ously described.20
Quantitative Reverse Transcription-Polymerase
Chain Reaction
Reverse transcription-polymerase chain reaction was performed to quan-
tify the expression of a variety of gene transcripts to have greater insight into
the relative presence of various cell types and growth factor expression
in the patches at 60 days after implantation (N ¼ 5 for each group), using
the TaqMan probe and Applied Biosystems 7700 sequence detector system
(Applied Biosystems, Foster City, Calif), as described.21 The tissues were
taken from the center of the patches and stored in a RNA stabilizationThe Journal of Thoracic and Careagent (RNAlater, Qiagen, Valencia, Calif). Transcripts that were analyzed
included von Willebrand factor, vascular smooth muscle a-actin 2, smooth
muscle 22a, vimentin, beta-myosin heavy chain (MHC), HGF, basic fibro-
blast growth factor, and VEGF. Beta-MHC was chosen because it was ex-
pressed in the early phase of cardiac growth as opposed to alpha-MHC,
whereas they were both positive in adult hearts.22,23 Results were normal-
ized to the level of porcine GAPDH transcripts. Relative expression to
GAPDH was quantified with standard curves for both a target gene and
GAPDH, ranging from 102 to 107 copies, which was created for each sample
and each assay. The sequences of the specific primers are listed in Table 1.
Histology and Immunohistochemistry
Excised tissues were fixed in 10% formalin for paraffin processing or
frozen and cut into 5-mm sections. The paraffin sections were deparaffinized
and stained with hematoxylin-eosin or prepared for immunohistochemical
staining. Monoclonal antibodies specific for factor VIII–related antigen
(Dako, Carpinteria, Calif) and a-smooth muscle actin (a-SMA) (Dako)rdiovascular Surgery c Volume 136, Number 5 1311
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Twere used. The immunoreaction was detected with 3,3-diaminobenzidine.
In addition, cryosections of the tissues were interacted with a-sarcomeric
actinin (Sigma, St Louis, Mo) and visualized with fluorescein isothiocya-
nate labeled secondary antibody, using a confocal microscope to detect car-
diomyocytes.
Capillary Density
The factor-VIII positive capillaries were counted under 2003 micros-
copy. Twenty fields were randomly selected in each patch. Capillary density
was expressed as the mean number of vessels per square millimeter.24
Statistical Analysis
All values are expressed as the mean standard deviation. The statistical
differences in all data were determined by the Mann–Whitney test.
RESULTS
In Vitro Analyses
HGF concentration was 571.8 246.7 ng/g dry weight in
the CBD-HGF-UBM patches and 163.9  183.3 ng/g dry
weight in the rHGF-UBM patches (P< .05) (Figure 2, A).
HGF was not detected in the untreated UBM patches.
CBD-HGF treatment of the UBM significantly increased
cell proliferation compared with HGF alone in both 80 ng/
disc (CBD-HGF 19.3  4.4 [3103] cells vs HGF 7.9 
TABLE 1. Primers and probes for quantitative reverse transcription-
polymerase chain reaction
GAPDH Forward 50-CTGCACCACCAACTGCTTAGC-30
Reverse 50-GCCATGCCAGTGAGCTTCC-3
Probe 50-CCTGGCCAAGGTCATCCATGACCACTTC-30
vWF Forward 50-ATGGAGTACACGGCTTTGCTG-30
Reverse 50-CAGGCACATGCTGTGACACAT-30
Probe 50-ATGAATGTCCACCTCCTCTTCAGACCGG-30
SM22a Forward 50-GCTCCATTTGCTTGAAGACCAT-30
Reverse 50-GTAATGCAGTGTGGCCCTGA-30
Probe 50-CTCAAAATCACGCCGTTCTTCAGCCA-30
ACTA2 Forward 50-TATGTGGCTATTCAGGCGGTG-30
Reverse 50-AGGATCTTCATGAGGTAGTCGGTG-30
Probe 50-ATGGTGTCACCCACAACGTGCCCATT-30
Vimentin Forward 50-AGGTGGCAATCTCAATGTCGA-30
Reverse 50-AAATGAGTACCGGAGACAGGTGC-30
Probe 50-CTCTTCCATTTCCCGCATCTGGCGTT-30
MHC Forward 5’-CTGAAGGACACCCAGATCCA-3’
Reverse 5’-GTTGATGAGGCTGGTCTGG-3’
Probe 5’-ACGCGGTCCGTGCCAATGATGACC-3’
HGF Forward 5’-ATGATGTCCACGGAAGAGGAGA-3’
Reverse 5’-CACTCGTAATAGGCCATCATAGTTGA-3’
Probe 5’-TGCAAACAGGTTCTCAATGTTTCCCAGC-
3’
bFGF Forward 5’-TGTGTGCAAACCGTTATCTTGCTA-3’
Reverse 5’-CAGTGCCACATACCAACTGGAGTA-3’
Probe 5’-CTACAATACTTACCGGTCGAGG-3’
VEGF Forward 5’-GACGTCTACCAGCGCAGCTACT-3’
Reverse 5’-TTTGATCCGCATAATCTGCATG-3’
Probe 5’-TTCCAGGAGTACCCCGATGAGATCGA-3’
ACTA2, Vascular smooth muscle a-actin 2; bFGF, basic fibroblast growth factor;
HGF, hepatocyte growth factor; MHC, beta-myosin heavy chain; SM22a, smooth
muscle 22a; VEGF, vascular endothelial growth factor; vWF, von Willebrand factor.1312 The Journal of Thoracic and Cardiovascular S2.4 [3103] cells; P < .05) and 400 ng/disc (CBD-HGF
29.5  2.8 [3103] cells vs HGF 20.8  3.2 [3103] cells;
P<.05) (Figure 2, B). The cell proliferation for UBM treated
with HGF alone at a concentration of 80 ng/disc was not sig-
nificantly different than that of the untreated UBM disc (9.1
 2.3 [3103] cells; P ¼ .58). In contrast, both treatments
with CBD-HGF showed statistically increased cell prolifer-
ation compared with the untreated UBM.
Clinical Outcome
All animals (N¼ 15) survived with no complications until
elective euthanasia at 60 days after initial surgery. No aneu-
rysmal change in the implanted patches was observed in any
of the groups at necropsy (Figure 1, C). Connective tissues
covered the epicardial side of the patch area with a slight ad-
hesion in the F and U groups. Severe adhesion was observed
between the Dacron patch and pericardium/lung (D group)
with deformity of the patch (Figure 1, D). A thin fibrous en-
capsulation was present on the endocardial side in the D
group that was easily separated from the patch. In the F
and U groups, the patches were completely replaced with
a white connective tissue with a thickness comparable to
that of the adjacent normal myocardial wall (Figure 1, E).
Electromechanical Mapping
Local unipolar and bipolar voltage electrograms were re-
corded. More than 200 discrete points were used to map the
right ventricle. Mean electrical activity in the patch regions
was 1.49  0.82 mV in the F group, which was statistically
greater than 0.93 0.71 mV in the U group and 0.30 0.22
mV in the D group (P< .05) and less than the normal myo-
cardium (8.24  2.49 mV; P< .05) (Figure 3, A). The LLS
was significantly improved in the F group (0.51% 1.57%)
compared with the U group (1.06% 1.84%; P<.05) and
the D group (2.72% 2.59%; P<.05), whereas they were
significantly inferior to the normal myocardium (13.7% 
4.3%; P< .05) (Figure 3, B).
Histology and Immunohistochemistry
Histologic examinations of the F group tissue showed nu-
merous cells through the entire patch, with a monolayer of
factor VIII positive cells on the endocardial surface of the re-
modeled patch (endothelial cells) and predominantly a-
SMA positive cells homogenously distributed through the
entire remodeled patch (Figure 4, A–C). In the U group,
the distribution and phenotypic expression of cells in the re-
modeled patch, as well as the thickness of the remodeled tis-
sue, were similar to those of the F group, with the exception
that a-SMA positive cells were predominantly localized at
the endocardial aspect and edges of the patch area (Figure 4,
D–F). In both the F and U groups, there was no UBM rem-
nant visible. In the D group, although a-SMA positive cells
were found through the entire patch region, the thickness of
the tissue was less than that of the F or U group (Figure 4,H).urgery c November 2008
Ota et al Evolving TechnologyFIGURE 2. In vitro testing. A, HGF determination in preimplant patches. The amount of HGF in the CBD-HGF-UBM patch was significantly higher than
that of the rHGF-UBM (*P< .05). B, Growth of human endothelial cells on UBM discs. CBD-HGF shows significantly greater proliferation potential than
HGF in each concentration (*P<.05).CBD-HGF-UBM, Collagen-binding domain/hepatocyte growth factor/urinary bladder matrix;DW, dry weight; rHGF,
recombinant hepatocyte growth factor;The host response to the Dacron patch was consistent with
a foreign body response (Figure 4, G). Within the tissue
that infiltrated the patch, scattered isolated islands of a-sar-
comeric actinin positive cells were observed in the F group
(17.1% of the tissue fields of the entire patch region in the
F group showed the presence of a-actinin positive cells), but
not in the U and D groups (Figure 4, I).
Capillary Density
The capillary density was the highest in the F group (31.7
 20.0/mm2) with a statistically significant difference, com-
pared with 14.3  10.5/mm2 in the U group and 4.6  4.4/
mm2 in the D group (Figure 5). A common characteristic inThe Journal of Thoracic and Cathe 3 groups was that the capillary structures were predom-
inantly distributed in epicardial aspect of the patches.
Quantitative Real-Time Reverse Transcription-
Polymerase Chain Reaction
mRNA expression was normalized by the expression of
a housekeeping gene (GAPDH). The results are summa-
rized in Table 2 and Figure 6. In the F and U groups, the
early mesenchymal markers (ie, vascular smooth muscle
a-actin 2, smooth muscle 22a, vimentin) were expressed
significantly more than in the normal myocardium. There
was also higher expression of mesenchymal markers in
the F group compared with the U group. Expression ofE
TFIGURE 3. A, Electrical activity in the patches. CBD-HGF-UBM patch shows the greatest electrical activity compared with the others (*P<.05). B, LLS of
the patch regions. CBD-HGF-UBM patch is positively contractile, whereas the UBM and Dacron patches are dyskinetic (*P< .05). CBD-HGF-UBM, Col-
lagen-binding domain/hepatocyte growth factor/urinary bladder matrix.rdiovascular Surgery c Volume 136, Number 5 1313
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TFIGURE 4. Histologic preparation of the patches 60 days after implantation. A, B, C, CBD-HGF-UBM patches show a monolayer of factor VIII positive
cells, and predominantly a-SMA positive cells homogenously spread to the entire patch area beneath the endothelial monolayer. D, E, F, UBM patches show
a-SMA positive cells predominantly distributed in the endocardial aspect and the edge of the patch area with an endocardial monolayer of factor VIII-positive
cells. G, H, Thickness of a-SMA positive cells is less than that of the CBD-HGF-UBM or UBM patches. Inflammatory reaction was seen along the Dacron
patch (arrow). I, CBD-HGF-UBM patch stained with a-sarcomeric actinin stain. Blue, green, and red indicate nuclei, phalloidin, and a-sarcomeric actinin,
respectively. A, D, G, Hematoxylin-eosin stain. B, E, H, a-SMA. C, F, Factor VIII. I, a-sarcomeric actinin. Black bar¼ 200 mm (3100). White bar¼ 100 mm
(3200). Da, Dacron; Epi, epicardial side; CBD-HGF-UBM, collagen-binding domain/hepatocyte growth factor/urinary bladder matrix; H.E., hematoxylin-
eosin; SMA, smooth muscle actin.von Willebrand factor was similar in the F and U groups
and was not statistically different from the normal myocar-
dium. In contrast, the expression levels of von Willebrand
factor, vascular smooth muscle a-actin 2, smooth muscle
22a, and vimentin were significantly higher in the D group
than in the other groups, including the normal myocardium,
which is consistent with the hyperplasic scar formation ob-
served histologically in the D group. The expression of
MHC in the F and U groups was detected with significantly
higher level in the F group, whereas it was not detected in
the D group. Both VEGF and basic fibroblast growth factor
were expressed significantly more in the F and U groups
than in the D group. The expression of HGF was greater
in the F group than in the U group (P< .05), whereas there
was no HGF detected in the normal myocardium and the D
group.1314 The Journal of Thoracic and Cardiovascular SDISCUSSION
The present study showed that the addition of CBD-HGF
to UBM increased proliferation of endothelial cells to
a greater extent than the untreated UBM. Histologic analyses
showed that the implanted CBD-HGF-UBM patches
resulted in constructive remodeling consisting of a mono-
layer of endothelial cells, well-organized myofibroblasts,
and scattered cells that are tentatively identified as cardio-
myocytes. One of the most important findings in this study
was that the CBD-HGF-UBM patch showed an improved
recovery of mechanical and electrophysiologic functions.
The CBD-HGF-UBM patches were positively contractile,
whereas the untreated UBM and Dacron patches were dyski-
netic. Likewise, recovery of the electrical activity in the
patches was the greatest in the CBD-HGF-UBM, although
it was far less than in the normal myocardium.urgery c November 2008
Ota et al Evolving TechnologyFIGURE 5. Capillary density and representative images. Representative factor VIII staining in each patch for capillary density study: A, CBD-HGF-UBM
patch. B, UBMpatch. C, Dacron patch. Black bar¼ 100 mm. D, Capillary density. CBD-HGF-UBMpatch shows highest capillary density of all (*P<.05). F,
CBD-HGF-UBM patch group. U, UBM patch group, D, Dacron patch group. Da, Dacron patch; CBD-HGF-UBM, collagen-binding domain/hepatocyte
growth factor/urinary bladder matrix.E
TThe morphologic observations and gene expression anal-
yses suggest that the reparative pathways for untreated UBM
patches and CBD-HGF-UBM patches were the same, but
that the rate of repair occurred more slowly for the untreated
UBM. In contrast, the host response to the Dacron patch was
more consistent with a chronic foreign body hyperplastic
response with scar tissue formation and the presence of
inflammatory cells. The results of histology and reverse
transcription-polymerase chain reaction indicate that the re-
paired tissues in the untreated UBM and CBD-HGF-UBM
patches are different from the typical myocardial scar. For
example, healed wound tissue from the Dacron patch-treated
hearts had no evidence for MHC gene expression or a-acti-
nin positive cells, markers that are commonly used to iden-
tify cardiomyocytes. The high expression of growth factors
(ie, VEGF, basic fibroblast growth factor, HGF) in the CBD-The Journal of Thoracic and CHGF-UBM and untreated UBM patches compared with
those in normal myocardium and Dacron patches suggests
that cells present in the UBM patches are participating in
the remodeling response.
The results emphasize the importance of rapid and aggres-
sive angiogenesis in the remodeled scaffold. In the untreated
UBM, the repopulated cells are localized on the endocardial
aspect and at the edges of the patch where blood supplies ex-
ist. The more uniform distribution of cells throughout the re-
modeled CBD-HGF-UBMwas associated with an increased
vascularity that implied increased blood supply. The mech-
anisms bywhich HGF promotes angiogenesis and the source
of the cells that populate the scaffold remain unclear. How-
ever, evidence shows a circulating source of progenitor cells,
including cells from the bone marrow, that is recruited to the
site of ECM remodeling.25-27TABLE 2. Results of quantitative real-time reverse transcription-polymerase chain reaction
Normal myocardium CBD-HGF-UBM (F) UBM (U) Dacron (D)
ACTA2 0.13  0.04 0.58  0.45a,b,c 0.25  0.25c 1.32  0.98a
SM22a 0.032  0.034 0.81  0.61a,b,c 0.23  0.22a,c 1.61  1.13a
Vimentin 0.11  0.03 1.39  1.03a,c 1.09  0.98a,c 3.15  2.47a
vWF 0.23  0.11 0.32  0.19c 0.27  0.07c 1.47  1.84a
MHC 5.82  1.24 1.65  0.67a,b 0.28  0.37a -
VEGF (3104) 9.68  11.27 14.97  11.4c 15.46  8.77c 3.14  3.36a
bFGF (3104) 2.31  1.82 339  198a,c 282  260a,c 23.4  24.2a
HGF (3104) - 2.24  0.82 0.6  0.27 -
ACTA2, Vascular smooth muscle a-actin 2; bFGF, basic fibroblast growth factor; HGF, hepatocyte growth factor; MHC, beta-myosin heavy chain; SM22a, smooth muscle 22a;
VEGF, vascular endothelial growth factor; vWF, vonWillebrand factor. Expressed with the mRNA level/GAPDH. P<.05. aVersus normal myocardium. bVersus UBM (U). cVer-
sus Dacron (D).ardiovascular Surgery c Volume 136, Number 5 1315
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TRecent studies have shown that non–cross-linked ECM
scaffolds promote an anti-inflammatory, accommodative
immune response, with an accumulation of macrophages
expressing the M2 phenotype.28 The treatment of ECM
scaffolds and tissues with crosslinking agents has been
advocated to slow degradation and increase mechanical in-
tegrity of the graft. The crosslinking process necessarily
eliminates the release of bioactive peptides that are benefi-
cial to the remodeling response (eg, bacteriostasis, chemo-
taxis, angiogenesis). Furthermore, chemically cross-linked
ECM scaffolds induce macrophages to express a proinflam-
matory phenotype that results in increased fibrous connec-
tive tissue formation.28
Study Limitations
There are several limitations to the present study. First, no
effort was made to examine electrical couplings and gap
junctions to prove regeneration of the conducting system.
Given the nascent signs of electrical remodeling (ie, sparse
myocytes, significant but slight electrical activity in the
patches), however, those electrical signals might be attrib-
uted to the aggregation of electrophysiologic activity by im-
mature mesenchymal cells.29,30 Second, the study only
evaluated a single time point. It is not clear how the remod-
FIGURE 6. Graphs of quantitative real-time reverse transcription-poly-
merase chain reaction. CBD-HGF-UBM, Collagen-binding domain/hepato-
cyte growth factor/urinary bladder matrix; ACTA2, vascular smooth muscle
a-actin 2; bFGF, basic fibroblast growth factor; MHC, beta-myosin heavy
chain; SM22a, smooth muscle 22a; VEGF, vascular endothelial growth fac-
tor; vWF, von Willebrand factor.1316 The Journal of Thoracic and Cardiovascular Sueling progresses in the period immediately after implantation
or in the long term, which should be investigated to fully
characterize the remodeled tissues. However, it is known
that naturally occurring ECM scaffolds degrade within 60
to 90 days after implantation,15,16 so any subsequent adapta-
tions of the myocardium would likely be a consequence of
remodeling in response to local environmental cues. Third,
an RV model was used to decrease mortality and morbidity
for the animal, and as a comparison with previous results.
Although a UBM patch manufactured by the identical
method described for the control patch has been shown to
be effective and durable for repair of the left ventricle,4 fur-
ther studies including the left ventricular model and a dis-
eased model (ie, infarction) are needed to determine the
efficacy of the CBD-HGF treatment to UBM. It is also im-
portant to test our patch in an infarcted heart model because
blood supplies to the implanted patch from the surrounding
tissue would be significantly reduced or completely shut off,
which might negatively influence myocardial remodeling in
the patch. Fourth, we did not investigate the impact of the
remodeled tissues on the global cardiac function. Given
the results of electrical activity and regional contractility in
this study, the functional contribution of the patch area might
be insignificant at 60 days after implantation. To make it
clear, we plan to use a catheter-based pressure-volume as-
sessment at sequential time points in the future study. Like-
wise, it is important to evaluate the synchronization between
the remodeled tissue and the surrounding myocardium using
such an echocardiography. Finally, the gene expression and
immunofluorescent staining are consistent with the appear-
ance of cells with cardiomyocyte characteristics in the car-
diac wounds repaired with CBD-HGF-UBM. The current
results cannot prove whether the HGF-UBM patch actually
stimulated cardiomyocyte regeneration in the cardiac
wound. Thus, a more rigorous analysis of additional cardio-
myocyte and cell proliferation markers will be necessary to
definitively identify the presence of newly regenerated cardi-
omyocytes in these repaired wounds.
CONCLUSIONS
The CBD-HGF-UBM patch demonstrated significantly
increased contractility and electrical activity compared
with UBM alone or Dacron, and facilitated a homogeneous
repopulation of host cells that may include cardiomyocytes.
UBM incorporated with CBD-HGF may contribute to site-
specific constructive myocardial remodeling as a substitute
for synthetic materials that are currently used for applica-
tions such as surgical ventricular restoration.
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